Thus, rapid evaluation of α1AT for the treatment of severe COVID-19 disease is highly warranted26,27,49,50 and four clinical trials (NCT04495101, NCT04385836, NCT04547140, EudraCT: 2020-001391-15) have been initiated to evaluate the therapeutic potential of α1AT in hospitalized COVID-19 patients. Here, SERPINA1 is linked to COVID-19.